Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Panel meeting prompts excitement for antiobesity drug.

Mullard A.

Lancet. 2012 Mar 10;379(9819):882. No abstract available.

PMID:
22413140
2.

The FDA's assessment of two drugs for chronic weight management.

Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C.

N Engl J Med. 2012 Oct 25;367(17):1577-9. doi: 10.1056/NEJMp1211277. No abstract available.

3.

Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.

Bays HE, Gadde KM.

Drugs Today (Barc). 2011 Dec;47(12):903-14. doi: 10.1358/dot.2011.47.12.1718738. Review. Erratum in: Drugs Today (Barc). 2012 Jan;48(1):95.

PMID:
22348915
4.

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.

Bays H.

Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Review.

PMID:
20707765
5.

2 new drugs for weight loss.

[No authors listed]

Med Lett Drugs Ther. 2012 Sep 3;54(1398):69-71. No abstract available. Erratum in: Med Lett Drugs Ther. 2012 Sep 17;54(1399):76.

PMID:
22992487
6.

Two anti-obesity hopefuls and their safety.

Bello NT, Campbell SC.

Expert Opin Drug Saf. 2012 Sep;11(5):681-3. doi: 10.1517/14740338.2012.706277. No abstract available.

PMID:
22788876
7.

Market watch: upcoming market catalysts in Q3 2010.

Hay M.

Nat Rev Drug Discov. 2010 Jul;9(7):507. doi: 10.1038/nrd3225. No abstract available.

PMID:
20592737
8.

New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).

Shyh G, Cheng-Lai A.

Cardiol Rev. 2014 Jan-Feb;22(1):43-50. doi: 10.1097/CRD.0000000000000001. Review.

PMID:
24304809
9.

Phentermine and topiramate extended-release for the obesity: new kids on the block.

Katsi V, Marketou M, Kallistratos MS, Tousoulis D, Makris T, Manolis AJ, Vardas P, Kallikazaros I.

Recent Pat Cardiovasc Drug Discov. 2013 Apr;8(1):35-41. Review.

PMID:
23565717
10.

Diet drugs Belviq and Qsymia receive FDA approval: what dentists need to know.

Wynn RL.

Gen Dent. 2013 Jan-Feb;61(1):11-3. No abstract available.

PMID:
23302354
11.

ACS chemical neuroscience molecule spotlight on Qnexa.

Mercer SL.

ACS Chem Neurosci. 2011 Apr 20;2(4):183-4. doi: 10.1021/cn200023v.

12.

Fixed-dose combination of phentermine-topiramate for the treatment of obesity.

Halpern B, Faria AM, Halpern A.

Expert Rev Clin Pharmacol. 2013 May;6(3):235-41. doi: 10.1586/ecp.13.13. Review.

PMID:
23656337
14.

Nonincretin drugs in later-stage development.

Zimmerman MP, Mehr SR.

Am J Manag Care. 2014 Jan;20(1 Spec No.):E2. No abstract available.

15.

Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.

Rubio MA.

Endocrinol Nutr. 2014 Dec;61(10):501-4. doi: 10.1016/j.endonu.2014.11.002. English, Spanish. No abstract available.

PMID:
25434595
17.

Phentermine plus topiramate in the treatment of obesity.

Malgarini RB, Pimpinella G.

Lancet. 2011 Jul 9;378(9786):125-6; author reply 126-7. doi: 10.1016/S0140-6736(11)61080-5. No abstract available.

PMID:
21742167
18.

Two new drugs approved for obesity.

Johnson AM.

S D Med. 2012 Sep;65(9):356-7. No abstract available.

PMID:
23066610
19.

Combination phentermine/topiramate for obesity treatment in primary care: a review.

Xiong GL, Gadde KM.

Postgrad Med. 2014 Mar;126(2):110-6. doi: 10.3810/pgm.2014.03.2746. Review.

PMID:
24685974
20.

Overview of new antiobesity drugs.

Hainer V.

Expert Opin Pharmacother. 2014 Oct;15(14):1975-8. doi: 10.1517/14656566.2014.946904. Review.

PMID:
25100293

Supplemental Content

Support Center